Foam and Liquid Sclerotherapy With or Without Herbal Gel for Small Vein Treatment

Summary

Telangiectasias (spider veins) and reticular veins represent early and common manifestations of chronic venous insufficiency . Telangiectasias are dilated intradermal venules or capillaries less than 1 mm in diameter and typically appear on the thighs, calves, or ankles in a red, pink, or purple hue. Reticular veins, measuring 1-3 mm, are dilated subdermal veins located slightly deeper and often function as feeder veins to telangiectasias. They are commonly blue or green and may cause discomfort or cosmetic concerns.

According to the CEAP classification (Clinical-Etiology-Anatomy-Pathophysiology), telangiectasias and reticular veins fall under class C1. Chronic venous insufficiency of the lower extremities is increasingly prevalent, affecting nearly one-third of women and one-fifth of men, and can lead to symptoms such as leg fatigue, cramps, swelling, skin changes, or in advanced cases, deep vein thrombosis or pulmonary embolism. Telangiectasias are often the first visible signs of CVI and are frequently treated for cosmetic purposes.

Sclerotherapy is a well-established treatment for C1 venous disease. It involves the injection of a sclerosant agent into abnormal veins, causing endothelial damage, inflammation, and eventual fibrosis and closure of the vein. Among the most commonly used sclerosants are detergent-type agents like sodium tetradecyl sulfate (STS) and polidocanol (POL), which have been used effectively in both liquid and foam forms.

Liquid sclerotherapy has been employed for over 160 years, offering a minimally invasive approach to treat superficial veins. Foam sclerotherapy, introduced by Orbach and further popularized in recent decades, involves mixing the sclerosant with air or gas to form a microbubble foam. This form has increased surface area contact with the endothelium, potentially enhancing efficacy, particularly in larger veins. However, debate remains regarding the relative safety and effectiveness of foam versus liquid sclerotherapy, especially for small vessels such as telangiectasias and reticular veins.

Several clinical studies, including those by Kaygin and Halici, have compared foam and liquid sclerotherapy in treating lower limb varicose veins. Both forms have demonstrated efficacy and acceptable safety profiles. Nonetheless, further research is needed to determine the optimal form of sclerotherapy, especially in relation to cosmetic outcomes, pain, patient satisfaction, and side effect profiles. This study aims to compare the effectiveness and safety of liquid versus foam sclerotherapy, with or without herbal application in the treatment of telangiectasias and reticular veins.

Conditions

• Telangectasia
• Reticular Veins

Interventions

PROCEDURE

Liquid sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure

Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure

PROCEDURE

Liquid sclerotherapy in telangectasia and reticular veins wit application of herbal gel post procedure

Liquid sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure

PROCEDURE

foam sclerotherapy in telangectasia and reticular veins without application of herbal gel post procedure

foam sclerotherapy injection of polidocanol in telangectasia and reticular veins without application of herbal gel post procedure

PROCEDURE

foam sclerotherapy in telangectasia and reticular veins with application of herbal gel post procedure

foam sclerotherapy injection of polidocanol in telangectasia and reticular veins with application of herbal gel post procedure

Sponsors & Collaborators

• Faculty of Medicine,Kafrelsheikh University, Egypt

  collaborator UNKNOWN

• Kafrelsheikh University

  lead OTHER

Principal Investigators

• moustafa hassan mabrouk, lecturer · faculty of medicine kfs university

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

65 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2024-09-05

Primary Completion

2025-08-05

Completion

2025-09-01

Countries

• Egypt

Study Locations